TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04705662

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lactulose breath test
Description: Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Stool sample
Description: Participants will provide a stool sample pre and post iron supplementation

Intervention type: OTHER
Group type: OTHER
Intervention: Daily Diary
Description: Monitoring stool form, consistency and frequency on a daily basis

Intervention type: OTHER
Group type: OTHER
Intervention: Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire
Description: Participants will complete the questionnaire pre and post iron supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Sulphate
Description: Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
Study: NCT06344897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: After appendicitis surgery, children will receive Kinesio taping in addition to the standard pain management applied in the clinic.
Study: NCT05861817

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser theapy
Description: participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser theapy
Description: participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
Study: NCT05844462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Oral Tadalafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT05502172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno \& Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
Study: NCT06293820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05408988

Intervention type: DIAGNOSTIC_TEST
Intervention: hs-TnT (high-sensitive cardiac troponin T) plasma concentration
Description: hs-TnT plasma concentration measured once every 12 hours

Intervention type: DIAGNOSTIC_TEST
Intervention: CK-MB (creatine kinase myocardial band) plasma concentration
Description: CK-MB plasma concentration measured every 12 hours

Intervention type: DIAGNOSTIC_TEST
Intervention: CPK (creatine phosphokinase) plasma concentration
Description: CPK plasma concentration measured every 12 hours

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration
Description: NT-proBNP plasma concentration measured every 12 hours

Intervention type: DIAGNOSTIC_TEST
Intervention: Metanephrine concentration in urine
Description: Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
Study: NCT05550519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: ETV will continue throughout screening and will be stopped at baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Description: TDF will continue throughout screening and will be stopped at baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Description: TAF will continue throughout screening and will be stopped at baseline.
Study: NCT06153550

Intervention type: OTHER
Intervention: preparation in Respiratory Physiotherapy
Description: preparation in Respiratory Physiotherapy consist to:~* 3 sessions per week with the physiotherapist~* spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery.
Study: NCT05262179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO0101
Description: 1 drop/ once or three times a day/ for 17 days divided into stage2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: 1 drop/ once or three times a day/ for 17 days divided into stage2
Study: NCT00013156

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Effectiveness of Lung Reduction Therapy
Study: NCT06576037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1019
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given by vein (IV)
Study: NCT05110612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
Study: NCT06576037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given by vein (IV)
Study: NCT05110612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Episodic Thinking
Description: Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
Study: NCT05731349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2018 Surviving Sepsis Campaign Hour-1 Bundle
Description: 1. Measure lactate~2. Obtain blood cultures before administering antibiotics~3. Administer broad-spectrum antibiotics based on local guidelines~4. Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~5. Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg
Study: NCT05212818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
Study: NCT05179200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasma donation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Description: Plasma donation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Whole blood donation
Description: Blood donation
Study: NCT06071585

Intervention type: OTHER
Intervention: Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis
Description: We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
Study: NCT06030362

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Dietary Supplement taken once daily for 3 months (90 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement taken once daily for 3 months (90days).
Study: NCT04989933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided erector spinae plane block
Description: Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided erector spinae plane block
Description: Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
Study: NCT06071585

Intervention type: OTHER
Intervention: Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis
Description: We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.

Intervention type: OTHER
Intervention: Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis
Description: We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
Study: NCT01173250

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: adding diverting ileostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: omitting diverting ileostomy
Study: NCT06064240

Intervention type: OTHER
Intervention: We do not have any intervention type
Description: We do not have any intervention type
Study: NCT05395585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual placental separation
Description: Manual separation of the placenta from uterus
Study: NCT05997745

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: study group
Description: Patients will receive early enteral locally nutrition postoperatively following surgery for peritonitis
Study: NCT06576037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Given by vein (IV)
Study: NCT05997745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: study group
Description: Patients will receive early enteral locally nutrition postoperatively following surgery for peritonitis
Study: NCT04148456

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Covered Endovacular Reconstruction of Aortic Bifurcation
Description: * The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~* After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~* A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~* The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation.
Study: NCT05429996

Intervention type: OTHER
Intervention: Skin Biopsy
Description: Skin biopsy specimens will be collected for both groups and subjected to quantitative nano histology using atomic force microscopy to assess for structural profile of a single collagen fibril

Intervention type: OTHER
Intervention: Skin Biopsy
Description: Skin biopsy specimens will be collected for both groups and subjected to quantitative nano histology using atomic force microscopy to assess for structural profile of a single collagen fibril
Study: NCT06425614

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autotransfusion
Description: ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.
Study: NCT05311878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-based perceptual training
Description: Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Behavior based perceptual training
Description: Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
Study: NCT06576037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)
Study: NCT06425614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Description: ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.
Study: NCT06576037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given by mouth
Study: NCT05203445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg intravenously q6weeks
Study: NCT04968912

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Treatment
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Study: NCT06022107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LDART
Description: LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
Study: NCT05693961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I plus
Description: CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
Study: NCT06436859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress ball group
Description: According to randomization, pregnant women in the intervention group will receive stress ball therapy during labor.
Study: NCT06341985

Intervention type: RADIATION
Intervention: Exclusive radiotherapy
Description: Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
Study: NCT06277167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human interferon alfa 1b inhalation solution
Description: Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human interferon alfa 1b inhalation solution placebo
Description: Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human interferon alfa 1b inhalation solution
Description: Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human interferon alfa 1b inhalation solution placebo
Description: Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).